The SCORES trial demonstrated that suvemcitug, when added to chemotherapy, significantly improved progression-free and overall survival in women with platinum-resistant ovarian cancer. Despite higher rates of adverse events in the suvemcitug group, the overall safety profile was manageable. The study indicates potential for suvemcitug in enhancing treatment outcomes for this population.
Study
|
Randomized, double-blind, placebo-controlled, phase 3 trial [SCORES, NCT04908787] |
| Women with ovarian cancer progressed within 6 months post platinum-based therapy |
| Suvemcitug (n=281) vs placebo (n=140) plus various chemotherapies (paclitaxel, topotecan, liposomal doxorubicin)
|
Efficacy
|
ORR: 26% vs 12.1% (suvemcitug vs. placebo) (p=0.001) |
| mPFS: 5.5 mos vs 2.7 mos (HR 0.46 [0.35-0.60]) |
| mOS: 15.3 mos vs 14.0 mos (HR 0.77 [0.60-0.99])
|
Safety
|
Grade >=3 AE: Neutropenia (49.8% vs 41.0%), Anemia (16.7% vs 17.3%) |
| TEAEs: Proteinuria (3.9% vs Not reported), Hypertension (18.9% vs 0.7%) |
| No suvemcitug-related grade 5 TEAEs
|
Nat Cancer. Published online 9 Jan, 2026
http://doi.org/10.1038/s43018-025-01085-z
Reviewed by Ulas D. Bayraktar, MD on Jan 21, 2026
